logo
Microplastics found in human semen, follicular fluid

Microplastics found in human semen, follicular fluid

CNN01-07-2025
Pollution
Water availability
Corporate newsFacebookTweetLink
Follow
Scientists have detected microplastics — the tiny and pervasive fragments now found in our seas, drinking water, food and, increasingly, living tissue — in human semen and follicular fluid, according to new research.
A small group of 25 women and 18 men participated in the research, published Tuesday in the journal Human Reproduction. Microplastics were detected in 69% of the follicular fluid samples and 55% of the seminal fluid samples. Follicular fluid is the liquid that surrounds an egg in an ovarian follicle.
The research is an abstract — a short summary of completed research — and has not yet been peer reviewed. It was presented Tuesday in Paris at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology.
'Previous studies had already suggested this possibility, so the presence of microplastics in the human reproductive system is not entirely unexpected,' said lead research author Dr. Emilio Gómez-Sánchez, director of the assisted reproduction laboratory at Next Fertility Murcia in Spain, in a statement provided to the press. 'What did surprise us, however, is how widespread it is. This is not an isolated finding — it appears to be quite common.'
Microplastics are polymer fragments that range in size from less than 0.2 inches (5 millimeters) to 1/25,000th of an inch (1 micrometer). Polymers are chemical compounds with long chains of large and repetitive molecular units called monomers, and are known for being flexible and durable. Most plastics are synthetic polymers.
Plastics smaller than the measurement criteria for microplastics are considered nanoplastics, which are measured in billionths of a meter.
'Microplastics primarily enter the body through three routes: ingestion, inhalation, and skin contact,' Gómez-Sánchez said. 'From there, they can enter the bloodstream, which then distributes them throughout the body, including to the reproductive organs.'
In previous studies, the fragments have also been detected in various body parts or fluids including the lungs, placenta, brain, testicles, nose tissue at the base of the brain, penises and human stool.
'Decades of studies and the (US Food and Drug Administration) agree that microplastics are not a threat because exposure is extremely low and they are non-toxic,' said Dr. Chris DeArmitt, founder of the Plastics Research Council, via email.
However, while there is little to nothing known about the potential effects of microplastics on human health, chemicals used in plastic production — that often leach from plastics — are linked with health risks including hormonal disruptions, certain cancers, respiratory diseases and skin irritation.
The research participants were patients and donors at Next Fertility Murcia. The women were undergoing egg retrieval, formally known as follicular aspiration, for assisted reproduction, while the men were undergoing semen analysis. The authors stored and froze the samples in glass, then incubated them for two days before analyzing them using an imaging technique combining microscopy and infrared laser.
The research team also analyzed the containers used to collect and store samples to ensure they hadn't been contaminated with microplastics. The abstract doesn't disclose what materials the collection containers were made of.
Imaging revealed nine types of microplastics in the reproductive fluids. Over 50% of the follicular fluid samples contained polyamide (PA), polyurethane (PU) and polyethylene (PE), while polytetrafluoroethylene (PTFE) and polyethylene terephthalate (PET) were discovered in over 30% of the follicular fluid samples.
Polypropylene (PP), polyvinyl chloride (PVC) and polylactic acid (PLA) appeared in over 20% of the follicular fluid samples.
In the semen samples, 56% contained PTFE.
Synthetic polyamide is commonly known as nylon, often used in textiles, plastics and automotive parts. Polyurethane is commonly used in coatings, foams and adhesives for furniture, construction, automotive parts, footwear and more. Polyethylene and polypropylene are often found in packaging, construction uses and consumer goods, such as toys and kitchenware.
The plastic PTFE is widely used in nonstick cookware, while PET is found in many food and beverage containers. Polyvinyl chloride is often used in the construction, packaging and medical industries, while PLA is primarily found in food packing, medical implants and 3D-printed objects.
In most samples, the researchers found only one or two particles, but they detected up to five in others, Gómez-Sánchez said. Microplastic concentrations were higher in follicular fluid than in semen. However, the overall concentrations of microplastics in both fluids were relatively low when compared with the concentrations of non-plastic particles. The abstract didn't disclose what those non-plastic particles were.
'Sadly, (the findings) are not surprising,' said Dr. Matthew J. Campen — a researcher who helped lead the discoveries of microplastics in the brain and testicles — via email.
Though the research is preliminary, it does 'set the stage for more advanced studies of the relationship between plastics exposure and reproductive fitness,' added Campen, who wasn't involved in the study and is a regents' professor of pharmaceutical sciences at the University of New Mexico.
The research affirmed previous studies that had found microplastics in these reproductive fluids, and yet again raises important questions, including how these microplastics are absorbed in the intestine then transported to the gonads, Campen said.
'This suggests a very natural mechanism is being hijacked,' he added. 'It would also be important to assess plastics in the nanoscale range.'
People trying to conceive naturally or via in vitro fertilization may not need to be concerned about the findings, as they are only preliminary for now, Gómez-Sánchez said.
'We don't know if they have a direct effect on the capacity of a couple to conceive and carry a baby to term,' he added. 'Reproduction is a complex equation, and microplastics are a variable in this equation.'
The findings also can't yet be linked to more general health outcomes, experts said.
'So far, the effects of microplastics on humans have been mainly extrapolated from animal studies, where microplastics were administered at high concentrations,' Gómez-Sánchez said. 'We currently lack direct evidence regarding their impact on humans.'
Betsy Bowers, executive director of the EPS Industry Alliance, echoed these disclaimers and noted that the animal research results aren't indicative of harm at regular exposure levels. The EPS (expanded polystyrene) Industry Alliance is a North American trade association representing the EPS industry.
The finding that follicular fluid contained more microplastics than semen may be circumstantial, Gómez-Sánchez added, because the study group was small. However, when an ovary is stimulated for assisted reproduction, blood flow to the ovary increases, which may deliver more microplastics to the ovary, he explained.
Additional research is needed to identify the types and quantities of microplastics that could cause health problems, said Dr. Ranjith Ramasamy, a consultant urologist at Jumeirah American Clinic in Dubai. Ramasamy, who wasn't involved in the study, led the research that found microplastics in penises.
'The plan is to increase the number of cases and conduct a survey on lifestyle habits in order to determine if any of these habits are linked to higher concentrations of plastics found in the ovaries and seminal plasma,' Gómez-Sánchez said.
Gómez-Sánchez and the other researchers also plan to explore whether the presence of microplastics in reproductive fluids affects the quality of sperm and oocytes, he said. Oocytes are cells in ovaries that form an ovum, a mature female reproductive cell that can divide to create an embryo upon fertilization by sperm.
The significance of the findings isn't yet clear, but they should be considered an additional argument in favor of avoiding the use of plastics in our daily lives, said Dr. Carlos Calhaz-Jorge, professor of obstetrics and gynecology at the University of Lisbon in Portugal, in a news release. Calhaz-Jorge wasn't involved in the research.
Given the ubiquity of plastics, avoidance can be challenging, said Dr. Philip Landrigan, a pediatrician and director of the Program for Global Public Health and the Common Good at Boston College, via email. In addition to reducing obvious uses of plastic, you can also avoid using plastic cutting boards and eating ultraprocessed foods.
Also limit drinking water from plastic bottles, microwaving food in plastic containers and consuming hot food from plastic containers, Ramasamy said.
Food can be stored in glass, stainless steel or bamboo instead of plastic.
But 'the conversation needs to shift — immediately — to policymakers,' Campen said. 'Hoping that individual choices can make a difference has been clearly a losing strategy. Federal governments around the world need to make major changes to waste management and recycling policies.'
Annual plastic production by weight has increased by 250 times in the past 75 years and is on track to triple again by 2060, Landrigan said.
'To reduce plastic pollution and safeguard human health, it will be essential that the Global Plastics Treaty that is currently in negotiation at the United Nations impose a global cap on plastic production,' Landrigan, who wasn't involved in the research, added.
'But smart governments can act now,' Campen urged.
Sign up for CNN's Life, But Greener newsletter. Our limited newsletter series guides you on how to minimize your personal role in the climate crisis — and reduce your eco-anxiety.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025

Yahoo

time11 minutes ago

  • Yahoo

Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025

Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For those of you who have signed up, we look forward to seeing you at the event. The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session. A link for the webcast of the plenary sessions will be available on our website closer to the date.​ The purpose of the event is to give institutional investors and financial analysts an introduction to the new 5-year strategy for the company, as well as to provide the opportunity to meet with the broader Management team. The day will start with a plenary session, covering the introduction of the new Group strategy, a financial update, and the strategy for the Chronic Care businesses. In the afternoon, participants will be split into groups and rotate between four Q&A breakout sessions. Participation in the breakout sessions will be in-person only (with a replay of the presentations available after the event). The formal program will end at 17.00, followed by an opportunity to meet the Coloplast management team in an informal setting. Agenda in CEST10.00 - 10.30 Registration10.30 - 12.30 Plenary session: Group strategy and financials, Chronic Care Commercial strategy12.30 - 13.00 Lunch break13.00 - 17.00 Q&A breakout sessions (incl. breaks)17.00 - 18.30 Social activity (on premise) Coloplast representatives Plenary session: Lars Rasmussen, Interim President and CEO Anders Lonning-Skovgaard, Executive Vice President, CFO Caroline Vagner Rosenstand, Executive Vice President, Chronic Care Commercial Breakout sessions: Chronic Care deep dive: Mike DelVacchio, Senior Vice President, North America Thomas Bruhn, Senior Vice President, Emerging Markets Wound & Tissue Repair: Fertram Sigurjonsson, Executive Vice President, Wound & Tissue Repair Bernd Greiner, Senior Vice President, Adv. Wound Dressings Interventional Urology: Thomas NP Johns Jr, Executive Vice President, Interventional Urology Global Operations and People & Culture: Allan Rasmussen, Executive Vice President, Global Operations Dorthe Rønnau, Executive Vice President, People & Culture * For more information,please contact: Aleksandra Dimovska, Vice PresidentDirect tel.: +45 4911 2458E-mail: dkadim@ Kristine Husted Munk, Sr. ManagerDirect tel.: +45 4911 3266E-mail: dkkhu@ Simone Dyrby Helvind, Sr. Manager Direct tel.: +45 4911 2981E-mail: dksdk@ Julie Sommer Müggler, Coordinator Direct tel.: +45 4911 3161Email: dkjusm@ Attachment Updated presenters list Coloplast CMD 2025

Can Weight Loss Boost Pregnancy Rates?
Can Weight Loss Boost Pregnancy Rates?

Medscape

timean hour ago

  • Medscape

Can Weight Loss Boost Pregnancy Rates?

A 10%-25% weight loss can help women considered overweight or having obesity become pregnant — even if they weren't trying to conceive — and reduce their chances for some pregnancy-related conditions and complications, according to a new study on reproduction. The study included patient data from nearly 250,000 women in the UK aged 18-40 years who had a BMI ≥ 25, which is considered overweight. BMI measures an estimate of body fat based on height and weight. Patients with obesity, who have a BMI ≥ 30, were also part of the study. Women in these categories who dropped the weight with a median loss of 14% had a small increase, about 5%, of becoming pregnant in the following 3 years compared with those with stable weight, according to the study published in Human Reproduction by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. The study used patient data collected from primary care practices linked to hospital records in England between January 2000 and May 2022. Nearly 80% of the women in the study kept a stable weight and the rest lost weight. Of the women who became pregnant (9%), those who lost weight had a 'statistically significant reduction' in the risk for gestational diabetes and emergency caesarean section, the study found. The women who lost weight also saw reduced pregnancy-induced hypertension with fewer babies born considered large for their gestational age compared with women of stable weight. Novo Nordisk — the maker of weight-loss drug Wegovy and diabetes drug Ozempic — funded the study, and most of the study authors work for the pharmaceutical company and/or hold shares or stock. Medscape Medical News asked a few clinicians, including Ob/Gyns with specialized training to treat patients with obesity, to weigh in on the study's findings. 'There is a lot of data to support that women that have obesity or are overweight have higher risks in their pregnancy but also have a more difficult time conceiving,' said Deidre Neyhart-McIntosh, MD, an Ob/Gyn with the Cleveland Clinic, Cleveland, who is trained in obesity medicine. The study shows that the healthier a woman can be prior to conceiving, the easier it will likely be for her to conceive and have a more successful pregnancy, McIntosh said. In her practice, McIntosh has seen that women who lose even 5% of their body weight can reduce their blood pressure, glucose, lipids, inflammation, and cardiovascular risk. McIntosh said she speaks with patients who want to be pregnant about the risks of having obesity, such as diabetes, hypertension, preeclampsia, pre-term delivery, or caesarian section of a large baby. She advises women to try to lose weight 6 months before they want to become pregnant and to study the habits that help them lose weight to continue eating healthy during pregnancy. Patients who are overweight may seek her help if they have difficulty becoming pregnant or have risk factors such as high blood pressure or prediabetes, she said. In those cases, McIntosh might discuss nutrition, exercise, or prescribe weight-loss medicine to help them improve their chances of a healthy pregnancy. McIntosh finds that most of her patients have tried other methods to lose weight before requesting weight-loss medicine. Depending on the medication, they should stop the drugs either immediately prior to conceiving or 2 months beforehand. Despite the study's connection to a weight-loss drug maker, McIntosh said she still believes the findings are valid. 'Obviously, we're going to pick out some of the biases, but overall, they looked at a wide variety of women and didn't focus on women that were just taking weight-loss medications either,' she said. Weight-Loss Medications The FDA has approved some of the newer medications for chronic weight management in adults with obesity, or if they are overweight, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Johanna Finkle, MD, an Ob/Gyn and weight-loss specialist with the University of Kansas Health System, Kansas City, Kansas, said that although the study doesn't specifically mention weight-loss drugs, a weight loss of 10%-25% is typically only seen in women taking the medicine for weight loss. From her experience, diet and exercise only produce a 3%-5% weight loss in a year, Finkle said. The study also cited previous research with different diets and exercise that didn't show decreased pregnancy complications or increased spontaneous conception, she noted. Finkle believes the new study looked at weight loss because women are losing significant weight on the medicines Novo Nordisk manufactures, namely GLP-1 receptor agonists. 'The question that they are trying to answer: Is this going to be beneficial to a preconception population and how much weight loss [is optimal] because these drugs are producing more weight loss than we see with diet and exercise alone,' she said. Optimal Weight Loss 'Right now, what we counsel is about 10% weight loss of body weight prior to pregnancy,' Finkle said. 'Any weight loss may be beneficial.' There are also risks to losing too much weight, especially in patients losing 30% of their body weight, she said. 'What I'm seeing in my patients is sometimes they're not consuming enough calories or even enough water,' Finkle said. 'I'm having to remind them that they need to eat more frequently. We discuss sufficient protein.' Others may experience hair loss. When patients lose a significant amount of weight, it can affect pregnancy. Patients who went through bariatric surgery have a risk for preterm delivery, Finkle said. 'I worry about small-for-gestational-age babies and an increased risk for miscarriage when people have a rapid trajectory of weight loss,' she said. Finkle said she counsels patients who are rapidly losing weight to try not to conceive while on the medication because 'the data on teratogenic risk of the weight-loss medications is not yet known.' Ideally, patients who want to lose weight before they conceive should come to her a year in advance, Finkle said. 'But if they're wanting to conceive in 3 months, then we discuss healthy behaviors, lifestyle, nutrition, and exercise counseling. We discuss: What is your goal? When do you want to conceive and how does weight loss play a role in that? How much weight loss can we achieve?' she said. Research Implications While previous research may have focused on the outcomes of women undergoing fertility treatment, the Novo Nordisk study wasn't restricted to women trying to conceive, so study authors said that the benefits of weight loss may be greater in women who are actively trying to become pregnant. Erin LeBlanc, MD, who conducts similar research about weight loss and pregnancy, believes the Novo Nordisk study provides further evidence that women having trouble becoming pregnant because they are overweight or have obesity could benefit from weight loss. In other words, if having a higher BMI is associated with decreased fertility rates, weight loss among that population could have the opposite impact, she said. LeBlanc, an epidemiologist and endocrinologist with the Kaiser Permanente Center for Health Research, said the Novo Nordisk study also aligns with research she led showing that women who lost weight had lower rates of gestational diabetes in early pregnancy. Because some women in the clinical trial gained weight back later in pregnancy, she stressed the importance of weight management throughout pregnancy. Women in her study who met with health coaches weekly for 6 months and then monthly for 18 months or until the end of their pregnancy were able to start pregnancy at a healthier weight. However, they experienced more weight gain during pregnancy, likely because it was challenging to maintain the healthy lifestyle changes they made prepregnancy without ongoing support, she said of the study originally published in 2021 in the American Journal of Obstetrics & Gynecology. ' What I would say from my research is that if women have been able to lose weight before pregnancy, they just need to be sure that they get support during pregnancy to help them to maintain a healthy lifestyle,' LeBlanc said. LeBlanc also said the new study may help inform future recommendations from the National Academy of Medicine, formerly the Institute of Medicine, which advised in 2009 that women achieve a healthy weight before becoming pregnant and remain within the gestational weight gain guidelines during pregnancy. Women with a healthy weight should gain 25-35 pounds; women who are overweight, 15-25 pounds; and women with obesity, 11-20 pounds, according to those guidelines. Study Limitations Among the limitations of the study, Finkle said using participants from the UK cannot necessarily be applied to those from the US. 'They did not cite the composition of their patient population,' she said. 'The United States is very diverse.' Finkle said that the median age of the patients (30 years) is also important to note. 'When you are talking about fertility, age plays a much larger role than necessarily body weight when looking at someone's ability to conceive.' Study authors said they didn't know whether women had intended to become pregnant or whether that intention was why they lost weight. Including women who don't intend to conceive may also affect the findings by underestimating the relationship between weight loss and chance of pregnancy, the authors said. And while they observed a link between weight loss and increased chance of pregnancy, they said they couldn't imply higher pregnancy rates were caused by weight loss. In her practice, Finkle often sees patients trying to lose weight prior to conception. 'So if more patients in the group that was actually trying to lose weight wanted to conceive, they're going to have higher rates of pregnancy than a weight stable group that maybe wasn't trying or had any intention of conceiving and were using maybe other methods to prevent pregnancy,' she said. Overall, Finkle found promising the study's finding of a small increase in conception from weight loss. She said more studies are needed to look at weight loss and pregnancy, including how weight gain during pregnancy affects the delivery and health of the mother and child. 'There's this phenomenon called weight cycling,' Finkle said. 'You may lose weight, then regain the same — or more — during pregnancy, and the question becomes: How will that affect outcomes such as large-for-gestational-age babies, cesarean-section deliveries, or hypertensive disorders? Many questions remain unanswered.'

Prenatal Metformin Shows Mixed Effects in PCOS
Prenatal Metformin Shows Mixed Effects in PCOS

Medscape

time2 hours ago

  • Medscape

Prenatal Metformin Shows Mixed Effects in PCOS

TOPLINE: Women with polycystic ovary syndrome (PCOS) who received metformin during pregnancy experienced a reduced rate of maternal infections, particularly viral infections. However, offsprings who were exposed to metformin in utero faced a high long-term risk for allergies and eczema. METHODOLOGY: Researchers in Norway conducted post hoc analyses of two randomised controlled trials and one follow-up study to examine immunologic effects of metformin in pregnant women with PCOS and in offsprings exposed to the medication in utero. They analysed the data of 634 pregnant women with PCOS who had been randomly assigned to receive either metformin (n = 316; median age, 30 years) or placebo (n = 332; median age, 30 years) from the first trimester to delivery. The effect of metformin exposure in utero was studied in 145 offsprings, with 74 and 71 being exposed to metformin and placebo in utero, respectively. Maternal clinical evaluations were performed at baseline and at regular intervals through gestational week 36, with self-reported maternal infections being recorded throughout pregnancy, delivery, and postpartum. Offsprings were evaluated for the diagnosis of any allergic condition such as asthma or eczema at a median age of nearly 8 years. TAKEAWAY: Women receiving metformin had fewer overall infections during pregnancy than those receiving placebo (odds ratio [OR], 0.68; 95% CI, 0.50-0.93), particularly viral infections (OR, 0.71; 95% CI, 0.51-0.99); the protective effect of metformin against viral infections was significant among women with obesity alone. Offsprings exposed to metformin in utero showed higher rates of allergy (OR, 4.83; 95% CI, 1.47-21.8) and eczema (OR, 2.42; 95% CI, 1.14-5.33) than those exposed to placebo in utero. Neither offspring BMI nor maternal infections during pregnancy modified the association between prenatal metformin exposure and the elevated risk for allergic conditions in offsprings. IN PRACTICE: "In the present study, metformin reduced the incidence of maternal infections during pregnancy while it increased the incidence of eczema and allergies in the offspring, suggesting that maternal infections might act as a protective factor," the authors wrote. "The adverse effects observed in the offspring highlight the need for caution when considering metformin treatment during pregnancy," they added. SOURCE: This study was led by Mariell Ryssdal, Norwegian University of Science and Technology, Trondheim, Norway. It was published online on August 11, 2025, in BJOG: An International Journal of Obstetrics & Gynaecology. LIMITATIONS: The original studies were not designed to assess metformin's effects on infections or allergic diseases. Maternal infections were self-reported and classified on the basis of symptoms without pathogen confirmation. Asthma, eczema, and allergies were diagnosed by doctors but reported by mothers without verification through medical tests. DISCLOSURES: This study was supported by The Liaison Committee for Education, Research, and Innovation in Central Norway; The Research Council of Norway; Novo Nordisk Foundation; and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store